Last reviewed · How we verify
Tetronine
Tetronine is a Small molecule drug developed by National Cardiovascular Center Harapan Kita Hospital Indonesia. It is currently in Phase 3 development. Also known as: Oral Triidothyronine (T3).
Tetronine, also known as sodium liothyronine, is being studied as a potential treatment for postoperative dysfunction following cardiac surgery and low T3 syndrome. It is being compared to a placebo and oral triiodothyronine in clinical trials.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Tetronine |
|---|---|
| Also known as | Oral Triidothyronine (T3) |
| Sponsor | National Cardiovascular Center Harapan Kita Hospital Indonesia |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia (PHASE3)
- Oral Triiodothyronine for Infants Less Than 5 Months & Malnourished Children Undergoing Cardiopulmonary Bypass in Indonesia (PHASE3)
- Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children? (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetronine CI brief — competitive landscape report
- Tetronine updates RSS · CI watch RSS
- National Cardiovascular Center Harapan Kita Hospital Indonesia portfolio CI
Frequently asked questions about Tetronine
What is Tetronine?
Who makes Tetronine?
Is Tetronine also known as anything else?
What development phase is Tetronine in?
Related
- Manufacturer: National Cardiovascular Center Harapan Kita Hospital Indonesia — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Oral Triidothyronine (T3)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing